Re-immunotherapy with Nivolumab Plus Ipilimumab in Advanced Non-Small Cell Lung Cancer Patients Previously Treated with Anti-Programmed Death-1 And/or Anti-Programmed Death Ligand-1 Antibodies.
DISCOVER ONCOLOGY（2023）
关键词
Cytotoxic T-lymphocyte-associated protein-4,Tumor proportion score,Immune checkpoint inhibitor,Immune-related adverse event,Objective response rate
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要